NCT05227820 - Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

July 20, 2022

Study Completion Date

August 20, 2022

Conditions

Alzheimer Disease

Interventions

DRUG

NE3107

Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)

Trial Locations (1)

Neurological Associates - The Interventional Group, Santa Monica